mainz biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. we develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.
Company profile
Ticker
MYNZ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mainz Biomed B.V.
SEC CIK
MYNZ stock data
Latest filings (excl ownership)
6-K
Announcement of Annual General Meeting of
24 Apr 24
6-K
Report of Foreign Private Issuer
19 Apr 24
20-F
2023 FY
Annual report (foreign)
8 Apr 24
6-K
Report of Foreign Private Issuer
23 Feb 24
6-K
Management’s Discussion and Analysis of Financial Condition and Results of Operations
16 Nov 23
6-K
Report of Foreign Private Issuer
15 Nov 23
424B5
Prospectus supplement for primary offering
14 Nov 23
6-K
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
13 Nov 23
424B5
Prospectus supplement for primary offering
26 Sep 23
6-K
Report of Foreign Private Issuer
13 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
0.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 59.22 mm |
Total shares | 20.15 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Greenwich Investment Management | 13.91 k | $41.00 mm |
JPM JPMorgan Chase & Co. | 2.57 k | $7.50 mm |
Steward Partners Investment Advisory | 1.50 k | $4.38 mm |
GWM Advisors | 1.00 k | $2.92 mm |
C Citigroup | 673.00 | $1.97 mm |
WFC Wells Fargo & Co. | 200.00 | $584.00 k |
MS Morgan Stanley | 200.00 | $584.00 k |
UBS UBS Group AG - Registered Shares | 98.00 | $286.00 k |
Proequities | 0.00 | $0.00 |
News
Mainz Biomed Reports Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers And Proprietary AI Algorithm For Integration Into Pivotal FDA PMA Clinical Trial For Next Generation Colorectal Cancer Diagnostic
25 Apr 24
Cantor Fitzgerald Reiterates Neutral on Mainz Biomed
12 Apr 24
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
10 Apr 24
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
2 Apr 24
Mainz Biomed Presents ColoAlert At UDH Congress 2024 For Evidence-Based Cancer Screening Innovations
12 Mar 24
Press releases
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
25 Apr 24
Mainz Biomed Reports Full Year 2023 Financial Results
9 Apr 24
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
19 Mar 24
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
12 Mar 24
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
5 Mar 24